Published in Gastroenterology on February 01, 1973
Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest (1998) 2.90
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut (1982) 1.60
Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol (1983) 1.59
Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut (1987) 1.57
Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut (1979) 1.43
Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Gut (1991) 1.40
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol (1982) 1.40
Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology (1999) 1.35
Inhibition of prostaglandin synthetase in human rectal mucosa. Gut (1983) 1.32
Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions (1986) 1.29
Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut (1981) 1.23
Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy. Gut (1986) 1.20
Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest (1982) 1.20
The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br J Pharmacol (1988) 1.18
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut (1985) 1.15
Pharmacological and biochemical actions of sulphasalazine. Drugs (1986) 1.05
Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils. Gut (1989) 1.05
Placental and mammary transfer of sulphasalazine. Br Med J (1979) 1.04
Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis. Br Med J (1977) 1.04
Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut (1987) 1.02
Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol (1999) 0.98
Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut (2004) 0.97
Molecular mechanisms of sulfasalazine-induced T-cell apoptosis. Br J Pharmacol (2002) 0.91
Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. Gut (1977) 0.91
Understanding and modulating mammalian-microbial communication for improved human health. Annu Rev Pharmacol Toxicol (2013) 0.89
Medical management of crohn disease. Clin Colon Rectal Surg (2013) 0.83
Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment. Ann R Coll Surg Engl (1990) 0.82
Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut (1989) 0.81
Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut (1988) 0.81
Drug therapy of ulcerative colitis. Br J Clin Pharmacol (1992) 0.81
Effect of sulphasalazine and sulphapyridine on neutrophil superoxide production: role of cytosolic free calcium. Ann Rheum Dis (1990) 0.79
Secretory effect of azodisalicylate (azodisal sodium) on the short circuited mucosa of the rat ileum in vitro. Gut (1988) 0.79
Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? World J Gastrointest Pharmacol Ther (2015) 0.77
Coexisting ankylosing spondylitis and gouty arthritis. Clin Rheumatol (2007) 0.76
Effects of processing on the release profiles of matrix systems containing 5-aminosalicylic acid. AAPS PharmSciTech (2012) 0.75
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease. Clin Exp Gastroenterol (2009) 0.75
Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell (1985) 7.29
Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J (1988) 3.77
Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners. Proc Natl Acad Sci U S A (1987) 3.18
Carbon-halogen bond cleavage. 3. Studies on bacterial halidohrolases. J Biol Chem (1968) 3.06
A uniform deleting element mediates the loss of kappa genes in human B cells. Nature (1985) 2.65
Nitrate synthesis in the germfree and conventional rat. Science (1981) 2.53
The serum digitalis concentration--does it diagnose digitalis toxicity? N Engl J Med (1976) 2.47
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci (1992) 2.47
Do medical devices have enhanced placebo effects? J Clin Epidemiol (2000) 2.45
Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest (1987) 2.39
The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther (1972) 2.37
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology (1993) 2.03
Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol (2000) 1.79
Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology (2001) 1.71
Drug therapy: metronidazole. N Engl J Med (1980) 1.66
Corticosteroid-associated complications in elderly Crohn's disease patients. Am J Gastroenterol (1997) 1.60
Gluten-sensitive enteropathy and systemic lupus erythematosus. Arch Intern Med (1988) 1.56
Cost-effectiveness of a new short-stay unit to "rule out" acute myocardial infarction in low risk patients. J Am Coll Cardiol (1994) 1.55
Gastrointestinal ailments of homosexual men. Medicine (Baltimore) (1982) 1.52
The metabolism of 2-fluorobenzoic acid. II. Studies with 18-O2. J Biol Chem (1968) 1.45
Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med (1984) 1.42
Urinary organic acid profiles in obese (ob/ob) mice: indications for the impaired omega-oxidation of fatty acids. Metabolism (1992) 1.42
Mesalamine-associated thrombocytopenia. Am J Gastroenterol (1999) 1.40
Drug therapy: Sulfasalazine. N Engl J Med (1975) 1.35
The carbon-fluorine bond in compounds of biological interest. Science (1969) 1.23
Mesalamine-induced lung toxicity. Am J Gastroenterol (1996) 1.22
How should we research unconventional therapies? A panel report from the Conference on Complementary and Alternative Medicine Research Methodology, National Institutes of Health. Int J Technol Assess Health Care (1997) 1.21
Caffeic acid metabolism by bacteria of the human gastrointestinal tract. J Bacteriol (1971) 1.21
The relationship between nitro group reduction and the intestinal microflora. J Pharmacol Exp Ther (1975) 1.21
Esophageal foreign body perforation: report of an unusual case and review of the literature. Am J Gastroenterol (1984) 1.17
Drug utilization and reported adverse reactions in hospitalized children. Am J Epidemiol (1979) 1.17
Acetamide--a metabolite of metronidazole formed by the intestinal flora. Biochem Pharmacol (1979) 1.15
The development of 5-nitroimidazoles for the treatment and prophylaxis of anaerobic bacterial infections. J Antimicrob Chemother (1982) 1.15
Metronidazole metabolism in cultures of Entamoeba histolytica and Trichomonas vaginalis. Antimicrob Agents Chemother (1981) 1.15
Relationship between metronidazole metabolism and bactericidal activity. Antimicrob Agents Chemother (1980) 1.13
The enzymatic hydrolysis of methotrexate and folic acid. J Biol Chem (1967) 1.08
The anaerobic metabolism of metronidazole forms N-(2-hydroxyethyl)-oxamic acid. J Pharmacol Exp Ther (1979) 1.06
Structural analysis of both products of a reciprocal translocation between c-myc and immunoglobulin loci in Burkitt lymphoma. Nucleic Acids Res (1985) 1.05
Ultrastructural immunogold localization of subcellular sites of TNF-alpha in colonic Crohn's disease. J Leukoc Biol (1995) 1.04
Caffeic acid metabolism by gnotobiotic rats and their intestinal bacteria. Proc Natl Acad Sci U S A (1972) 1.04
Studies on avian erythrocyte metabolism. Inositol tetrakisphosphate: the major phosphate compound in the erythrocytes of the ostrich (Struthio camelus camelus). Eur J Biochem (1977) 1.04
Residue specificity of a ribonuclease which hydrolyzes polycytidylic acid. J Biol Chem (1970) 1.00
The association between the myelodysplastic syndromes and Crohn disease. Ann Intern Med (1992) 0.99
Treatment demands and differential treatment of patients with cystic fibrosis and their siblings: patient, parent and sibling accounts. Child Care Health Dev (2001) 0.97
The avian apoprotein II very low density lipoprotein gene. Methylation patterns of 5' and 3' flanking regions during development and following induction by estrogen. J Biol Chem (1982) 0.97
5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochem Pharmacol (1987) 0.97
Nurse specialist in family planning. Br Med J (1976) 0.97
Carbon-fluorine bond cleavage. II. Studies on the mechanism of the defluorination of fluoroacetate. J Biol Chem (1966) 0.96
Carboxypeptidase G: purification and properties. Proc Natl Acad Sci U S A (1967) 0.95
Will there be a next generation of sulfasalazine? Gastroenterology (1982) 0.94
Abdominal epilepsy. A cause of abdominal pain in adults. JAMA (1978) 0.93
Cloning and structural characterization of an estrogen-dependent apolipoprotein gene. J Biol Chem (1981) 0.93
5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther (1995) 0.93
T cell receptor alpha-, beta-, and gamma-genes in T cell and pre-B cell acute lymphoblastic leukemia. J Clin Invest (1987) 0.92
The resource utilization group system: its effect on nursing home case mix and costs. Inquiry (1991) 0.92
Ileoanal pouch operation: long-term outcome with or without diverting ileostomy. Arch Surg (2000) 0.90
Squamous cell papilloma of the esophagus. Report of a case after peptic esophagitis and repeated bougienage with review of the literature. Gastroenterology (1978) 0.90
Biochemical pharmacology of the intestinal flora. Annu Rev Pharmacol Toxicol (1978) 0.89
Utilization of the poison center for the teaching of clinical toxicology to medical and pharmacy students, housestaff, and health care professionals. Clin Toxicol (1979) 0.88
Rate-controlled drug delivery. N Engl J Med (1982) 0.88
The management of propoxyphene poisoning. J Pediatr (1974) 0.87
Esophageal motor dysfunction in systemic lupus erythematosus. Two cases with unusual features. JAMA (1979) 0.87
One against the plague. Newsweek (1986) 0.87
Autoimmune (Hashimoto's) thyroiditis associated with Crohn's disease. J Clin Gastroenterol (1998) 0.87
Recent advances in inflammatory bowel disease. Crit Rev Clin Lab Sci (2001) 0.86
Interaction of metronidazole with DNA repair mutants of Escherichia coli. Antimicrob Agents Chemother (1984) 0.86
The powerful placebo: doubting the doubters. Adv Mind Body Med (2001) 0.86
Metabolites from the reduction of metronidazole by xanthine oxidase. Mol Pharmacol (1980) 0.86
Inflammatory bowel disease in the elderly. Practical treatment guidelines. Drugs Aging (1997) 0.85
Metronidazole: proven benefits and potential risks. Johns Hopkins Med J (1980) 0.85
Therapeutic implications of the intestinal microflora. N Engl J Med (1973) 0.84
Properties and reactions of salicyl-coenzyme A. Biochem Pharmacol (1970) 0.84
Laparoscopically assisted ileocolectomy for Crohn's disease through a pfannenstiel incision. Am J Surg (2000) 0.83
Nitrate production and phagocyte activation: differences among Sprague-Dawley, Wistar-Furth and Lewis rats. Carcinogenesis (1988) 0.83
Risks to children from computed tomographic scan premedication. JAMA (1982) 0.83
Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J Pharmacol Exp Ther (1973) 0.83
Segmental colitis associated with Aeromonas hydrophila. Am J Gastroenterol (1989) 0.83
The reduction of N-hydroxy-4-acetylaminobiphenyl by the intestinal microflora of the rat. Cancer Res (1975) 0.83
Crohn's disease in the elderly. Am J Gastroenterol (1981) 0.83
Drug ingestions associated with miosis in comatose children. J Pediatr (1976) 0.83
Fluorocitric acid: selective microbial degradation of the inhibitory isomer. Biochem J (1970) 0.82
Comparing the reduction of nitroimidazoles in bacteria and mammalian tissues and relating it to biological activity. Biochem Pharmacol (1986) 0.82
Metabolism of guanidinosuccinic acid. I. Characterization of a specific amidino hydrolase from Pseudomonas chlororaphis. J Biol Chem (1972) 0.82
Effect of salt on prostaglandin metabolism in hypertension-prone and -resistant Dahl rats. Hypertension (1981) 0.82
Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis (2010) 0.82
Emergencies in inflammatory bowel disease. Crit Care Clin (1995) 0.82
Formation of an amino reduction product of metronidazole in bacterial cultures: lack of bactericidal activity. Biochem Pharmacol (1987) 0.81
Errors in measuring drug concentrations. N Engl J Med (1978) 0.81
The enzymatic hydrolysis of folate analogues. Biochem Pharmacol (1968) 0.81
Inflammatory bowel disease and pregnancy: a review. Dig Dis (1999) 0.81
Association of salmonella mutants with germfree rats: site specific model to detect carcinogens as mutagens. Proc Natl Acad Sci U S A (1975) 0.81
Metabolism of drugs by microorganisms in the intestine. Am J Clin Nutr (1974) 0.81
A metronidazole metabolite in human urine and its risk. Science (1981) 0.81
Physical activity in first-degree relatives of breast cancer patients. J Behav Med (2001) 0.81